We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SEKISUI XenoTech Announces Expanded Consultation For Drug Developers
Product News

SEKISUI XenoTech Announces Expanded Consultation For Drug Developers

SEKISUI XenoTech Announces Expanded Consultation For Drug Developers
Product News

SEKISUI XenoTech Announces Expanded Consultation For Drug Developers


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "SEKISUI XenoTech Announces Expanded Consultation For Drug Developers"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SEKISUI XenoTech has announced the opportunity for clients to work with top-tier consultants to analyze critical components of absorption, distribution, metabolism, and excretion (ADME) of their drug candidate to optimize the data package for regulatory submission.

Larry Wienkers, Ph.D., of Wienkers Consulting, LLC stated “The journey of a drug’s development is like a well-told story—you use elemental components of biology and chemistry to establish the pharmacological underpinnings of a molecule’s journey within a patient. Gathering the data for a submission is telling that story; it is very important not to miss any pieces”. When a drug is being developed, it goes through a very rigorous battery of safety assessments to prove it poses minimal risks to participants in clinical trials. Approval is only granted when exhaustive information is presented to detail parameters such as pharmacology, toxicology, and ADME.

With an emphasis on cultivating expertise in ADME, SEKISUI XenoTech has assembled a lineup of consultants who can equip our clients with highly specialized insight borne of years of experience in the industry and extensive scholarship. The consulting team is being led by Brian Ogilvie, Ph.D., who serves as SEKISUI XenoTech’s Vice President of Scientific Consulting and has over 20 years of experience at the company. 


Advertisement